Max Hodak’s Science Corp. is preparing to implant its first brain sensor in a human patient, a move that positions the neurotechnology startup as a serious contender in the brain-computer interface space. The company has raised $230 million to advance its work, and expects regulatory approval by mid-2026.
For those of us watching the AI agent space, this matters more than you might think. Brain-computer interfaces aren’t just about helping people with disabilities anymore—they’re becoming the next frontier for how humans might interact with AI systems. And Hodak, who co-founded Neuralink before starting Science Corp., knows this territory better than almost anyone.
What Science Corp. Is Actually Building
Science Corp.’s approach focuses on a retinal implant called PRIMA. This is a wireless device designed to restore vision for people with certain types of blindness. The company has submitted a CE mark application to the European Union and is awaiting a decision from the Food and Drug Administration in the United States.
The timing is interesting. By targeting mid-2026 for approval, Science Corp. is moving fast but not recklessly. They’re taking a measured path through regulatory channels, which suggests they’ve learned from the challenges other brain-interface companies have faced.
Why This Matters for AI Agents
Here’s where things get interesting for the AI agent community. Brain-computer interfaces represent a potential leap in how we might control and interact with AI systems. Right now, we’re stuck with keyboards, mice, and voice commands. These are all external interfaces that create friction between thought and action.
Imagine an AI agent that could respond directly to neural signals. You wouldn’t need to type out a prompt or speak a command. The latency between intention and execution would collapse. This isn’t science fiction—it’s the logical endpoint of the technology Science Corp. and others are developing.
The $230 million funding round tells us that investors see this potential too. That’s serious money for a company that’s still working toward its first human implant. It suggests confidence not just in the medical applications, but in the broader platform these technologies might enable.
The Neuralink Connection
Hodak’s history with Neuralink adds context here. He left that company in 2021, and Science Corp. represents his vision for how brain interfaces should develop. The fact that he’s focusing on vision restoration first—rather than Neuralink’s broader brain-reading ambitions—suggests a different strategic approach.
Starting with a specific medical application makes regulatory approval more straightforward. It also builds a foundation of real-world data and experience that could support more ambitious applications later. This is the kind of strategic thinking that makes Science Corp. worth watching.
What Happens Next
The mid-2026 timeline for regulatory approval is aggressive but achievable. If Science Corp. hits that target, we’ll see the first human implant shortly after. That’s when the real learning begins—not just for the company, but for the entire field of brain-computer interfaces.
For AI developers and agent builders, this technology is still a few years away from practical integration. But the trajectory is clear. The companies that start thinking now about how AI agents might interface with neural signals will have an advantage when these systems become available.
Science Corp.’s progress also raises questions about data privacy, consent, and the ethics of brain-reading technology. These aren’t abstract concerns—they’re practical challenges that will need solutions before neural interfaces can scale beyond medical applications.
The appointment of Murat GĂĽnel as Medical Director for Brain-Computer Interfaces in March 2026 signals that Science Corp. is building the medical expertise needed to navigate these challenges. This isn’t just an engineering problem; it’s a medical, ethical, and regulatory puzzle that requires multiple types of expertise.
For now, Science Corp. remains focused on its vision restoration mission. But the implications extend far beyond that initial application. The first human brain sensor implant will be a milestone not just for the company, but for the future of human-AI interaction.
đź•’ Published: